Actively Recruiting
Study of Omalizumab Injections for Adults 40 and Older with COPD and Indoor Allergies
Led by Johns Hopkins University · Updated on 2026-09-04
334
Participants Needed
23
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the drug omalizumab to see if it helps people aged 40 and older who have Chronic Obstructive Pulmonary Disease COPD and are allergic to common indoor allergens such as pet dander, cockroaches, or dust mites. This study focuses on individuals who have allergen exposure in their homes and aims to assess the rate of COPD exacerbations over 12 months. The trial is sponsored by Johns Hopkins University and is a randomized, placebo-controlled phase 2 study. Participants receive subcutaneous injections of either omalizumab or a placebo normal saline at a clinic. The dose and frequency of injections are determined by weight and blood test results, with injections given either monthly 12 doses or twice monthly 24 doses. The active treatment follows a dosing schedule similar to that used for asthma. The study includes about 1 to 3 months of screening, 12 months of receiving the study drug, and a follow-up call one month after the final clinic visit. During the trial, participants visit the clinic for their injections and are monitored for side effects after each dose. Researchers will measure how often participants experience COPD exacerbations during the 12-month treatment period. The total participation lasts about 16 months, including screening, treatment, and follow-up. Participants must continue their usual inhaled therapies, and safety is monitored throughout the study.
CONDITIONS
Brief Title
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
Research Team
K
Kayla Long
H
Heather Hazucha
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here